Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

McMaster University

$105,000.00

Stakeholder perspectives and preferences for implementation of pharmacogenomic (PGx) testing in primary care in Ontario, Canada.

FY 2021-22

Summary
It is increasingly understood that drug response is partly influenced by genetics. Using pharmacogenomic (PGx) testing, it is possible to determine whether individuals possess genetic variant(s) involved in drug response. Implementation of PGx testing might lead to fewer adverse drug reactions and greater adherence to prescribed medications. PGx testing may be particularly useful in primary care since this is where most medication prescription and dispensation occurs, and 60% of primary care patients are prescribed a drug for which PGx information is available. Despite this, PGx testing is not yet widely performed in the clinical setting and in Canada has not been implemented at all in primary care. This may be due to lack of evidence on PGx test accuracy; lack of economic evidence; or patient concerns (for example, regarding privacy). Given the benefits and challenges of PGx testing, stakeholder evidence is needed to inform whether and how this type of testing should be implemented in primary care. This research examines stakeholder perspectives and preferences to inform health policy and funding decision making about implementation of PGx testing in primary care. I will conduct three studies. First, I will review PGx clinical practice guidelines from around the world to understand when this type of testing is appropriate and for whom. Next, I will conduct semi-structured interviews with stakeholders such as patients, primary care providers, and policy makers about their views on implementation and public coverage (i.e., OHIP) of PGx testing. Finally, I will conduct a discrete choice experiment (DCE) asking participants to choose between different hypothetical policy options for PGx testing. I will compare interview results from the second study with results from the DCE to understand how stakeholders' stated preferences differ from their actual preferences. This research will contribute to developing PGx policy that reflects stakeholders' preferences and values.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
458553
Name
Cernat Alexandra
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Health systems / services
Prcname2
Doctoral Research Awards - B
Projecttitle
Stakeholder perspectives and preferences for implementation of pharmacogenomic (PGx) testing in primary care in Ontario, Canada.
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Discrete Choice Experiment; Genetics; Health Policy; Health Services Research; Health Technology Assessment; Mixed Methods Research; Perspectives, Preferences, And Values Research; Pharmacogenomics; Qualitative Description; Stakeholder Engagement
Abstract
It is increasingly understood that drug response is partly influenced by genetics. Using pharmacogenomic (PGx) testing, it is possible to determine whether individuals possess genetic variant(s) involved in drug response. Implementation of PGx testing might lead to fewer adverse drug reactions and greater adherence to prescribed medications. PGx testing may be particularly useful in primary care since this is where most medication prescription and dispensation occurs, and 60% of primary care patients are prescribed a drug for which PGx information is available. Despite this, PGx testing is not yet widely performed in the clinical setting and in Canada has not been implemented at all in primary care. This may be due to lack of evidence on PGx test accuracy; lack of economic evidence; or patient concerns (for example, regarding privacy). Given the benefits and challenges of PGx testing, stakeholder evidence is needed to inform whether and how this type of testing should be implemented in primary care. This research examines stakeholder perspectives and preferences to inform health policy and funding decision making about implementation of PGx testing in primary care. I will conduct three studies. First, I will review PGx clinical practice guidelines from around the world to understand when this type of testing is appropriate and for whom. Next, I will conduct semi-structured interviews with stakeholders such as patients, primary care providers, and policy makers about their views on implementation and public coverage (i.e., OHIP) of PGx testing. Finally, I will conduct a discrete choice experiment (DCE) asking participants to choose between different hypothetical policy options for PGx testing. I will compare interview results from the second study with results from the DCE to understand how stakeholders' stated preferences differ from their actual preferences. This research will contribute to developing PGx policy that reflects stakeholders' preferences and values.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Cernat, Alexandra
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
McMaster University - $105,000 Grant (2021-22) | Canada Spends